Rolf Bambauer¹*, Ralf Schiel², Octavio J Salgado³and Richard Straube (2024) Adv Res Dermatol Cosmetics 3: 1017

Severe and/or refractory dermatological diseases with immunologic origin to conventional therapy have a bad
prognosis. Autoimmune blistering diseases have a high morbidity and mortality. Therapeutic apheresis is an essential supportive treatment for severe and refractory dermatological diseases with an immunologic origin, particularly autoimmune blistering diseases. This approach has been shown to significantly improve the prognosis of these diseases.
Therapeutic apheresis, combined with immunosuppressive therapy and/or human monoclonal antibodies, has treated successfully autoimmune blistering skin disorders. These diseases are caused by the immune system’s targeting of structural proteins in the skin and/or mucous membranes. Improved diagnostic methods have allowed to determine that the incidence and prevalence of these disorders have doubled in the last 15 years to 25 new cases per million people per year owing to an aging population. Over the last 45 years, therapeutic apheresis, in combination with immunosuppression and/or human monoclonal antibodies, has significantly increased survival rates. Therapeutic apheresis using hollow fiber modules is safe and highly effective in eliminating autoantibodies and other toxins from the bloodstream, leading to rapid clinical improvement in dermatological conditions. The guidelines of the for American Application Committee of the American Society for Apheresis are cited dermatologic disorders, which could be treated with therapeutic apheresis

Giuseppina Perrone ¹, Roberto Brunelli ¹, Eleonora Marcoccia ¹, Ilaria Zannini ¹, Miriam Candelieri ¹, Maria Gozzer ², Claudia Stefanutti ³

When approaching TA in pregnancy, clinicians have to consider the severity of disease, the strength of the indications, and the gestational age. Each case must be evaluated individually on the basis of existing evidence since, despite the increasing use, specific guidelines for apheresis in pregnancy are still lacking.

https://pubmed.ncbi.nlm.nih.gov/27412826/

The selective therapeutic apheresis procedures.

J. Clin. Apheresis 28:20–29, 2013  doi:10.1002/jca.21265 

Selective apheresis procedures have been developed to target specific molecules, antibodies, or cellular elements
in a variety of diseases. The advantage of the selective apheresis procedures over conventional therapeutic plasmapheresis is preservation of other essential plasma components such as albumin, immunoglobulins, and clotting
factors. These procedures are more commonly employed in Europe and Japan, and few are available in the
USA. Apheresis procedures discussed in this review include the various technologies available for low-density
lipoprotein (LDL) apheresis, double filtration plasmapheresis (DFPP), cryofiltration, immunoadsorption procedures, adsorption resins that process plasma, extracorporeal photopheresis, and leukocyte apheresis.

https://onlinelibrary.wiley.com/doi/abs/10.1002/jca.21265